National Coalition for LGBTQ Health
Home » Resource Library

Fact Sheet: Update on the Biden-⁠Harris Administration’s Commitment to Addressing the Global Mpox Outbreak

Access This Resource
Resource Type
Subject Areas
Associated Programs

Archived update from the White House from December 2024. During the 2022 global outbreak of clade II mpox, the Biden-Harris Administration mounted a robust response by making vaccines, tests, and treatment available to those at risk in the United States and abroad.

Related Resources

CDC: Interim Clinical Considerations for Use of Vaccine for Mpox Prevention in the United States

Two vaccines can be used to prevent mpox: JYNNEOS® and ACAM2000®, but only JYNNEOS has been used in the ongoing clade II outbreak. Healthcare providers should evaluate and counsel patients who could benefit from mpox vaccination by performing a social and sexual history.

View Item

Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.

JYNNEOS®, the only FDA-approved mpox vaccine, is now commercially available in the U.S.

View Item
National Coalition for LGBTQ Health

1630 Connecticut Ave. NW, Suite 500
Washington, DC 20009

202-232-6749 | [email protected]

Main Menu
Advocacy Learning Research About the Coalition
Additional Resources
HealthHIV HealthHCV PleasePrEPMe.org SYNChronicity Conference

© Copyright 2025 National Coalition for LGBTQ Health. All rights reserved. | Privacy Policy | Site Map